ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

OVID Ovid Therapeutics Inc

1.04
-0.11 (-9.57%)
16 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Ovid Therapeutics Inc NASDAQ:OVID NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.11 -9.57% 1.04 0.81 3.00 1.19 1.03 1.17 437,654 05:00:11

Ovid Therapeutics to Present at Upcoming September Investor Conferences

04/09/2024 1:00pm

GlobeNewswire Inc.


Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart


From Aug 2024 to Nov 2024

Click Here for more Ovid Therapeutics Charts.

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that management will participate in two upcoming investor conferences in September:

  • H.C. Wainwright 26th Annual Global Investment Conference – Ovid will present on September 10th at 3:30 p.m. ET.
  • Cantor Global Healthcare Conference – Ovid will participate in a fireside chat on Tuesday, September 17th at 1:55 p.m. ET.

Live webcasts of the fireside chat and presentation can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation.

About Ovid TherapeuticsOvid Therapeutics Inc. is a New York-based biopharmaceutical company that is dedicated to improving the lives of people affected by rare epilepsies and brain conditions with seizure symptoms. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. Ovid is developing: OV888/GV101 capsule, a potent and highly selective ROCK2 inhibitor, for the potential treatment of cerebral cavernous malformations and other rare central nervous system diseases; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. For more information about these and other Ovid research programs, please visit www.ovidrx.com.

Investor Relations:Garret Bonney617-735-6093gbonney@ovidrx.com

1 Year Ovid Therapeutics Chart

1 Year Ovid Therapeutics Chart

1 Month Ovid Therapeutics Chart

1 Month Ovid Therapeutics Chart